[1] Lan KKG, Lachin JM, David L.Discrete sequential boundaries for clinical trials[J]. Biometrika,1983,70(3):659-663. [2] 郭静,何大卫. 期中分析:一种新的临床试验设计方法[J]. 中国卫生统计,2000,17(2):111-113. [3] Christopher Jennison,Bruce W.Turnbull. Two-Sided Tests: Introduction[M]//Christopher Jennison,Bruce W. Turnbull. Group Sequential Methods with Applications to Clinical Trials. CHAPMAN & HALL/CRC,1999. [4] van der Lee JH, Wesseling J, Tanck MW,et al. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases[J]. J Clin Epidemiol,2008,61(4):324-330. [5] 徐端正,于莉莉. 成组序贯检验[M]//金丕焕,陈峰,主编. 医用统计方法(第三版). 上海:复旦大学出版社,2009:320-324. [6] 郭静,何大卫. 期中分析方法在临床试验中的应用[J]. 山西医科大学学报,2001,23(6):506-509. [7] Vandemeulebroecke M.Group sequential and adaptive designs - a review of basic concepts and points of discussion[J]. Biom J,2008,50(4):541-557. [8] 武俊青,高尔生,郭静,等. 随机化临床试验的期中分析名义检验水准及样本含量[J]. 数理医学杂志,2000,13(1):33-35. [9] 李先涛,梁伟雄,张伯礼. 简单介绍成组序贯设计在临床试验中的应用[J]. 中国临床药理学与治疗学,2006,11(12):1433-1436. [10] 于浩,陈晓媛,柏建岭,等. 肿瘤新药Ⅱ期临床试验中的多阶段设计[J]. 肿瘤,2008,28(1):68-73. [11] DeSouza CM, Legedza AT, Sankoh AJ. An overview of practical approaches for handling missing data in clinical trials[J]. J Biopharm Statist,2009,19(6):1055-1073. [12] 李婵娟,蒋志伟,王锐,等. 随机对照药物临床试验样本量估计[J]. 中国临床药理学与治疗学,2011,16(10):1132-1136. |